{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:55:53Z","timestamp":1792580153753,"version":"4.5.0"},"reference-count":46,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","award":["CNTO1275CRD4031"],"award-info":[{"award-number":["CNTO1275CRD4031"]}],"id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2026,7,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fistulising perianal Crohn\u2019s disease (CD) remains a debilitating condition, with few randomised controlled trials conducted so far.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the efficacy and safety of ustekinumab (UST) in patients with CD with active draining perianal fistulas (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04496063\">NCT04496063<\/jats:ext-link>\n                      ) in a randomised placebo-controlled trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>In this double-blind, multicentre Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives trial, patients enrolled with active fistulising perianal CD were randomised 1:1 to receive UST (6\u2009mg\/kg intravenously at baseline followed by 90\u2009mg subcutaneously at week 8, then every 8 weeks) or placebo, after standardised surgical management. The primary endpoint was combined clinical remission (absence of drainage from all external fistula openings) and radiological remission (absence of abscesses &gt;2\u2009cm on blinded central MRI) at week 12. At week 12, placebo non-responders could switch to UST, and UST non-responders could be intensified during the open-label phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>32 patients were randomised (UST: 16; placebo: 16) across 10 French centres and 69% had prior anti-tumour necrosis factor failure. At week 12, combined remission was achieved in 62% with UST versus 25% with placebo (OR=5.1 (95% CI 1.07\u201324.4)). Clinical remission occurred in 62.5% vs 31% (OR=3.75 (95% CI 0.84 to 16.8)) and radiological remission in 87.5% vs 75% (OR=2.7 (95% CI 0.34 to 21.1)). Nine placebo-patients switched to UST during the open-label phase. Combined remission rates at week 48 were 50% in the placebo arm and 31% in the UST arm, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest greater short-term clinical benefit with UST compared with placebo and support its use in patients with active fistulising perianal CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04496063\">NCT04496063<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2026-339158","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:25:16Z","timestamp":1784913916000},"page":"gutjnl-2026-339158","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Ustekinumab for fistulising perianal Crohn\u2019s disease: a randomised placebo-controlled trial from the GETAID"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct04496063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04496063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04496063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05347095","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pauline","family":"Wils","sequence":"first","affiliation":[{"name":"Gastroenterology, CHRU de Lille, Lille, France"},{"name":"Infinite, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Gastroenterology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre Benite, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Messmer","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Centre Hospitalier de Roubaix, Roubaix, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4903-3535","authenticated-orcid":false,"given":"Arnaud","family":"Bourreille","sequence":"additional","affiliation":[{"name":"Institut des Maladies de l\u2019Appareil Digestif (IMAD) \u2013 Gastroenterology department, CIC Inserm-04, University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-409X","authenticated-orcid":false,"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University Hospital Estaing, Inserm, CHU Clermont-Ferrand, 3iHP, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4110-1866","authenticated-orcid":false,"given":"Ludovic","family":"Caillo","sequence":"additional","affiliation":[{"name":"Gastroenterology, University Hospital Centre Nimes, Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Gastroenterology, Centre Hospitalier Universitaire de Besancon, Besancon, France"},{"name":"INSERM Right 1098, Universit\u00e9 Marie et Louis Pasteur, Universite de Franche-Comte, Besancon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Hepato-gastroenterology Department, Saint-Eloi Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[{"name":"Gastroenterology and clinical nutrition, CHU Nice, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ernst","sequence":"additional","affiliation":[{"name":"Medical Imaging Department, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Meunier","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Laurent","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nancy University Hospital, Universit\u00e9 de Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4273","authenticated-orcid":false,"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[{"name":"Immunology Department, Saint-Etienne University Hospital Bellevue Site, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"Centre Medico-chirurgical Magellan, H\u00f4pital Haut-L\u00e9v\u00eaque, Gastroenterology department, Hopital Haut-Leveque, Universit\u00e9 de Bordeaux ; INSERM CIC 1401, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Department of Methodology, Unit\u00e9 de recherche clinique Lariboisi\u00e8re Saint-Louis\u2013 URC, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072410251307000_gutjnl-2026-339158v1.1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32362"},{"key":"2026072410251307000_gutjnl-2026-339158v1.2","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e31825228b0"},{"key":"2026072410251307000_gutjnl-2026-339158v1.3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4291\/wjgp.v5.i3.205","article-title":"Pathophysiology of fistula formation in Crohn\u2019s disease","volume":"5","author":"Scharl","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01561.x"},{"key":"2026072410251307000_gutjnl-2026-339158v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"2026072410251307000_gutjnl-2026-339158v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"2026072410251307000_gutjnl-2026-339158v1.7","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000148"},{"key":"2026072410251307000_gutjnl-2026-339158v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31203-X"},{"key":"2026072410251307000_gutjnl-2026-339158v1.9","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","article-title":"OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn\u2019s Disease: results from the global ADMIRE-CD II phase 3 study","volume":"18","author":"Serclova","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026072410251307000_gutjnl-2026-339158v1.10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjae003","article-title":"Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn\u2019s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial","volume":"18","author":"Reinisch","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026072410251307000_gutjnl-2026-339158v1.11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn\u2019s disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.15665","article-title":"Vedolizumab for perianal Crohn\u2019s disease: a multicentre cohort study in 151 patients","volume":"51","author":"Chapuis-Biron","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072410251307000_gutjnl-2026-339158v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.032"},{"key":"2026072410251307000_gutjnl-2026-339158v1.14","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1093\/ibd\/izaf162","article-title":"Long-term Outcomes of Patients with Crohn\u2019s Disease Treated with Risankizumab","volume":"31","author":"Geeganage","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026072410251307000_gutjnl-2026-339158v1.15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3748\/wjg.v28.i9.961","article-title":"Relationship between clinical remission of perianal fistulas in Crohn\u2019s disease and serum adalimumab concentrations: A multi-center cross-sectional study","volume":"28","author":"Sirmai","year":"2022","journal-title":"World J Gastroenterol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.16","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/724813"},{"key":"2026072410251307000_gutjnl-2026-339158v1.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04466.x"},{"key":"2026072410251307000_gutjnl-2026-339158v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03232.x"},{"key":"2026072410251307000_gutjnl-2026-339158v1.19","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"2026072410251307000_gutjnl-2026-339158v1.20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","article-title":"Effectiveness of adalimumab in perianal fistulas in crohn\u2019s disease patients naive to anti-TNF therapy","volume":"49","author":"Casta\u00f1o-Milla","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"2026072410251307000_gutjnl-2026-339158v1.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"2026072410251307000_gutjnl-2026-339158v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.005"},{"key":"2026072410251307000_gutjnl-2026-339158v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.09.018"},{"key":"2026072410251307000_gutjnl-2026-339158v1.25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072410251307000_gutjnl-2026-339158v1.26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072410251307000_gutjnl-2026-339158v1.27","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.14309\/ajg.0000000000000810","article-title":"Ustekinumab for Perianal Crohn\u2019s Disease: The BioLAP Multicenter Study From the GETAID","volume":"115","author":"Chapuis-Biron","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.28","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(17)30930-7","article-title":"Fistula Healing in Pivotal Studies of Ustekinumab in Crohn\u2019s Disease","volume":"152","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2026072410251307000_gutjnl-2026-339158v1.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030939","article-title":"Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn\u2019s Disease: A Retrospective Real-World Analysis","volume":"12","author":"Yao","year":"2023","journal-title":"J Clin Med"},{"key":"2026072410251307000_gutjnl-2026-339158v1.30","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.dld.2025.08.091","article-title":"Durable clinical and deep remission with ustekinumab in perianal fistulizing Crohn\u2019s disease: A 2-year retrospective real-world cohort study","volume":"57","author":"Chen","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026072410251307000_gutjnl-2026-339158v1.31","unstructured":"Anon . Available: https:\/\/eposters.ddw.org\/ddw\/2022\/ddw-2022\/353546\/bruce.sands.perianal.fistula.closure.in.patients.receiving.ustekinumab.results"},{"key":"2026072410251307000_gutjnl-2026-339158v1.32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00330-024-11029-3","article-title":"External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn\u2019s disease","volume":"35","author":"Beek","year":"2025","journal-title":"Eur Radiol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cgh.2025.02.009","article-title":"Defining Radiological Healing in Perianal Fistulizing Crohn\u2019s Disease: A TOpClass Global Expert Delphi Consensus","volume":"24","author":"Anand","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"2026072410251307000_gutjnl-2026-339158v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00877-1"},{"key":"2026072410251307000_gutjnl-2026-339158v1.36","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304488"},{"key":"2026072410251307000_gutjnl-2026-339158v1.37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i23.2597"},{"key":"2026072410251307000_gutjnl-2026-339158v1.38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw169"},{"key":"2026072410251307000_gutjnl-2026-339158v1.39","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(26)06754-5","article-title":"1058b Guselkumab for perianal fistulizing Crohn's disease: Week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study","volume":"170","author":"Peyrin-Biroulet","year":"2026","journal-title":"Gastroenterology"},{"key":"2026072410251307000_gutjnl-2026-339158v1.40","doi-asserted-by":"crossref","first-page":"102045","DOI":"10.1016\/j.eclinm.2023.102045","article-title":"Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn\u2019s perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial","volume":"61","author":"Meima - van Praag","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026072410251307000_gutjnl-2026-339158v1.41","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of Reinduction and\/or Dose Escalation of Ustekinumab in Crohn\u2019s Disease: A Systematic Review and Meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.42","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ibd\/izad065","article-title":"Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease","volume":"30","author":"Vasudevan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026072410251307000_gutjnl-2026-339158v1.43","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12876-025-04323-x","article-title":"Ustekinumab trough concentrations predict clinical remission in perianal fistulizing crohn\u2019s disease: a real-world retrospective cohort study","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026072410251307000_gutjnl-2026-339158v1.44","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332489"},{"key":"2026072410251307000_gutjnl-2026-339158v1.45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333281"},{"key":"2026072410251307000_gutjnl-2026-339158v1.46","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20608"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2026-339158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:25:20Z","timestamp":1784913920000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2026-339158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":46,"alternative-id":["10.1136\/gutjnl-2026-339158"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2026-339158","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}